GLP-1 receptor agonists (GLP-1RAs) such as exenatide, liraglutide and semaglutide have emerged as new therapeutic options for PCOS due to their clear benefits in the treatment of metabolic disorders [102]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.